Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't

Ireland's Jazz pays $1.5bn to acquire Celator and its hotly anticipated leukemia drug, Vyxeos; Spero takes over antibacterial program out-licensed by Vertex; Novartis to copromote Eisai's Lenvima.

The Pink Sheet regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between May 21-June 3. Deal Watch is supported by deal intelligence provided by Strategic Transactions

.

More from United States

More from North America